Arbutus Biopharma Corp Translation Adjustment Functional to Reporting Currency, Net of Tax, Period Increase (Decrease)
Arbutus Biopharma Corp (ABUS) reported Translation Adjustment Functional to Reporting Currency, Net of Tax, Period Increase (Decrease) of $44.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-03.
Discontinued › Notes › Foreign Currency Translation
us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease · last filed 2022-03-03
- Arbutus Biopharma Corp translation adjustment functional to reporting currency, net of tax, period increase (decrease) for the quarter ending 2020-09-30 was $44.00K, a 62.96% increase year-over-year.
- Arbutus Biopharma Corp translation adjustment functional to reporting currency, net of tax, period increase (decrease) for the quarter ending 2019-09-30 was $27.00K.
- Arbutus Biopharma Corp translation adjustment functional to reporting currency, net of tax, period increase (decrease) for the quarter ending 2019-06-30 was -$52.00K.
- Arbutus Biopharma Corp translation adjustment functional to reporting currency, net of tax, period increase (decrease) for the quarter ending 2019-03-31 was -$22.00K.
- Arbutus Biopharma Corp translation adjustment functional to reporting currency, net of tax, period increase (decrease) for fiscal 2020 was $44.00K.
- Arbutus Biopharma Corp translation adjustment functional to reporting currency, net of tax, period increase (decrease) for fiscal 2019 was -$59.00K.
| Period end | Translation Adjustment Functional to Reporting Currency, Net of Tax, Period Increase (Decrease) 3 month | Translation Adjustment Functional to Reporting Currency, Net of Tax, Period Increase (Decrease) 6 month | Translation Adjustment Functional to Reporting Currency, Net of Tax, Period Increase (Decrease) 9 month | Translation Adjustment Functional to Reporting Currency, Net of Tax, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2020-12-31 | $44.00K 10-K · filed 2022-03-03 | |||
| 2020-09-30 | $44.00K 10-Q · filed 2021-11-04 | |||
| 2019-12-31 | -$59.00K 10-K · filed 2021-03-04 | |||
| 2019-09-30 | $27.00K 10-Q · filed 2020-11-05 | -$25.00K derived: sum of 2 quarters · filed 2020-11-05 | -$47.00K derived: sum of 3 quarters · filed 2020-11-05 | |
| 2019-06-30 | -$52.00K 10-Q · filed 2020-11-05 | -$74.00K derived: sum of 2 quarters · filed 2020-11-05 | ||
| 2019-03-31 | -$22.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |